Vaccine Panel Retreats from mRNA Covid Review Before Midterms

A major federal panel that advises the government on vaccines has stepped back from efforts targeting Covid-19 mRNA vaccines, a change that comes as some Republicans reportedly caution that additional shifts in vaccine policy could hurt the party in the upcoming midterm elections.

Several vaccine advisers selected by Robert F Kennedy Jr, the health secretary, had been exploring the possibility of ending federal recommendations for mRNA covid shots. That initiative is no longer going forward, according to two sources familiar with the discussions who spoke to the Washington Post.

The shift represents a retreat from the panel's previous considerations to reevaluate the federal guidance on mRNA Covid vaccines, which have been a central part of the country's pandemic response. The mRNA vaccines, developed by Pfizer-BioNTech and Moderna, have been widely used and credited with saving millions of lives worldwide.

The decision to step back from the mRNA vaccine review comes as some Republican lawmakers have raised concerns about the potential political fallout of altering vaccine policy ahead of the crucial midterm elections, where control of Congress is at stake.

The vaccine advisory panel's work has drawn scrutiny and criticism from both sides of the political aisle. Some Democrats have accused the panel of being influenced by anti-vaccine activists, while some Republicans have raised concerns about the panel's objectivity and potential to undermine public confidence in vaccination efforts.

The retreat from the mRNA vaccine review represents a notable shift in the panel's approach, indicating a potential acknowledgment of the complex political landscape surrounding Covid-19 policies and the need to navigate it carefully as the midterm elections approach.

The decision to step back from the mRNA vaccine review underscores the delicate balance the panel must strike between its scientific mandate and the political realities it faces. As the country continues to grapple with the ongoing pandemic, the panel's actions will likely be closely watched and scrutinized by both the public and policymakers.